Social Media-based Patient Education and Active Self-report on Incidence and Outcomes of Adverse Events in Natural Killer/T-cell Lymphoma (NK/TCL) Patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Extranodal NK-T-Cell Lymphoma, Nasal Type
- Sponsor
- Rong Tao
- Enrollment
- 665
- Locations
- 2
- Primary Endpoint
- overall survival
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
The purpose of this study is to collect data from patients by social media and self-report on the adverse events and outcomes happened with patients with extranodal natural killer/T-cell lymphoma, nasal type, who are treated outside of clinical trials in China.
Detailed Description
Extranodal natural killer/T-cell lymphoma, nasal type, is a rare subtype of non-Hodgkin lymphoma with relatively high incidence in China. L-asparaginase based chemotherapy are widely used with Chinese patients and has been reported to improve overall response and prolonged the long-term survival in some clinical trials with very limited patients. However, most patients were treated out of clinical trials in China. Therefore the real incidence of adverse events and treatment outcomes are largely unknown. This study is designed to evaluate the incidence of adverse events and treatment outcomes by social media-based (www.house086.com, www.wechat.com) self-report from patients who are treated out of clinical trials.
Investigators
Rong Tao
Clinical Professor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility Criteria
Inclusion Criteria
- •Pathological diagnosis of extranodal natural killer/T-cell lymphoma, nasal type based on WHO 2008 classification of tumors of haematopoietic and lymphoid tissue.
- •Treated with at least one cycle of L-asparaginas or Pegaspargase based chemotherapy.
- •Signed Informed consent.
Exclusion Criteria
- •patients who are enrolled in any other clinical trials.
- •Relapsed patients who were initially treated with non-L-asparaginas or non-pegaspargase based regimens.
Outcomes
Primary Outcomes
overall survival
Time Frame: 2-year
The overall survial time of patients will be measured since the initiation of treatment to death of any reason.
Secondary Outcomes
- Progression free survival(2-year)
- Treatment-Related Adverse Events as Assessed by CTCAE v4.0(Day 1 of each course of chemotherapy and radiotherapy then every 3 months for 2 years)